Results 51 to 60 of about 2,144 (203)
Whole genome sequencing and prediction of antimicrobial susceptibilities in non-tuberculous mycobacteria [PDF]
, 2022 Non-tuberculous mycobacteria (NTM) are opportunistic pathogens commonly causing chronic, pulmonary disease which is notoriously hard to treat.
Lipman, M +3 more
core +1 more source
Frontiers in Microbiology, 2020 Carbapenem-resistant Acinetobacter nosocomialis (CRAn) is a significant public health concern. Tigecycline non-susceptible CRAn (Tn-CRAn) isolates have emerged worldwide.
Yi-Tzu Lee +9 more
doaj +1 more source
Omadacycline Enters the Ring: A New Antimicrobial Contender [PDF]
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2018 Omadacycline is a novel aminomethylcycline approved for the treatment of community‐acquired bacterial pneumonia and acute bacterial skin and skin structure infections. This article reviews existing data pertaining to the biochemistry, mechanism of action, pharmacokinetics/pharmacodynamics, in vitro activity, and current progress with omadacycline in ...
Katie E. Barber +4 more
openaire +2 more sources
Acquisition and Spread of Antimicrobial Resistance : A tet(X) Case Study [PDF]
, 2021 Peer reviewedPublisher ...
Aminov, Rustam
core +1 more source
Foot & Ankle Surgery: Techniques, Reports & Cases, 2023 : Background: Surgical wound dehiscence (SWD) is one of the most common complications of surgical incision sites after foot surgeries because of blood flow and circulation issues that may occur in the foot. Such SWD complications can potentially lead to
Philip Wrotslavsky
doaj +1 more source
Emerging antibiotics for community-acquired pneumonia [PDF]
, 2019 Introduction: Community-acquired pneumonia is the most common infection leading to hospitalization and death in all age groups, especially in elderly populations.
Cillóniz, Catia +3 more
core +1 more source
Pharmacokinetics and Pharmacodynamics of Oral and Intravenous Omadacycline [PDF]
Clinical Infectious Diseases, 2019 AbstractOral and intravenous (IV) omadacycline formulations are approved in the United States for treating acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia in adults. Oral omadacycline bioavailability is 34.5%; similar exposures are obtained following 300 mg oral and 100 mg IV doses.
Rodvold, Keith A, Pai, Manjunath P
openaire +2 more sources
Preliminary, real-world, multicenter experience with omadacycline for Mycobacterium abscessus infections [PDF]
, 2021 Twelve patients were treated with omadacycline (OMC) as part of a multidrug regimen ...
Alosaimy, Sara +14 more
core +2 more sources
New antibiotics for the treatment of acute bacterial skin and soft tissue infections in pediatrics [PDF]
, 2020 Acute bacterial skin and soft tissue infections (aSSTIs) are a large group of diseases that can involve exclusively the skin or also the underlying subcutaneous tissues, fascia, or muscles.
Argentiero A. +4 more
core +2 more sources
mSphereTreatment outcomes for Mycobacteroides abscessus (Mab, also known as Mycobacterium abscessus) disease are still unsatisfactory, mainly due to issues with drug toxicity, tolerability, and efficacy.
Elisa H. Ignatius +7 more
doaj +1 more source